| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| olokizumab | interleukin-6 | biotech | Successful target | TTD , drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Rheumatoid Arthritis[MeSHID:D001172] Disease[MeSHID:D004194] |
10.18 | investigational,phase 3 | antagonist |
| olokizumab | interleukin-6 | biotech | Successful target | TTD , drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
10.18 | investigational,phase 3 | antagonist |
| olokizumab | interleukin-6 | biotech | Successful target | TTD , drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Rheumatoid Arthritis[MeSHID:D001172] Disease[MeSHID:D004194] |
10.18 | investigational,phase 3 | antagonist,inhibitor |
| olokizumab | interleukin-6 | biotech | Successful target | TTD , drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
10.18 | investigational,phase 3 | antagonist,inhibitor |
| click here to return to the previous page | ||||||||